Use of Zevalin to Enhance the Efficacy of Non-Myeloablative Allogeneic Transplantation in Patients With Relapsed or Refractory CD20+ Non-Hodgkins Lymphoma
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Antithymocyte globulin; Ciclosporin; Ciclosporin; Mycophenolate mofetil; Mycophenolate mofetil; Rituximab
- Indications Graft-versus-host disease; Non-Hodgkin's lymphoma
- Focus Biomarker; Therapeutic Use
- 05 Jan 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
- 20 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 29 Jun 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2018.